文献速递胸部肿瘤消化系统肿瘤泌尿男性生殖肿瘤

雷莫芦单抗联合帕博利珠单抗治疗经治晚期非小细胞肺癌、胃食管癌或尿路上皮癌(JVDF):多队列、非随机、开放标签、1a/b期试验

Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
PubMed 文献 · Lancet Oncol · 2019-07-10

本研究为多队列、非随机、开放标签1a/b期试验,纳入92例经治晚期胃或胃食管交界腺癌、非小细胞肺癌或尿路上皮癌患者,评估雷莫芦单抗联合帕博利珠单抗的安全性和初步抗肿瘤活性。主要终点为安全性,结果显示治疗相关不良事件发生率为82%,3级及以上治疗相关不良事件发生率为24%,客观缓解率在胃或胃食管交界腺癌队列为7%、非小细胞肺癌队列为30%、尿路上皮癌队列为13%。

要点

  • 雷莫芦单抗联合帕博利珠单抗在经治晚期胃食管癌、非小细胞肺癌和尿路上皮癌中安全性可控。
  • 非小细胞肺癌队列客观缓解率达30%,胃食管癌队列为7%,尿路上皮癌队列为13%。
  • 常见治疗相关不良事件为疲劳,3级及以上最常见为高血压和结肠炎。

核心结论

  • 雷莫芦单抗联合帕博利珠单抗在经治晚期胃或胃食管交界腺癌、非小细胞肺癌和尿路上皮癌患者中显示出可控的安全性和有利的抗肿瘤活性。

研究设计与样本

  • 多队列、非随机、开放标签1a/b期试验,在美国、法国、德国、西班牙和英国的16个学术医疗中心、医院和诊所进行。
  • 纳入92例经治晚期胃或胃食管交界腺癌(41例)、非小细胞肺癌(27例)或尿路上皮癌(24例)成人患者,ECOG体能状态0-1。
  • 帕博利珠单抗200 mg静脉给药第1天,雷莫芦单抗静脉给药8 mg/kg第1和8天(队列A)或10 mg/kg第1天(队列B、C、D),每3周一次。

主要发现

  • 治疗相关不良事件发生于92例中的75例(82%),最常见为疲劳(33例[36%]),多为1或2级。
  • 22例(24%)发生一个或多个3级及以上治疗相关不良事件,最常见为高血压(6例[7%])和结肠炎(5例[5%])。

关键数值与推荐

  • 1a期安全性导入期(n=11)中,一例接受8 mg/kg雷莫芦单抗的胃食管交界腺癌患者出现3级腹痛、结肠炎、肝炎、间质性肺病和黄疸,以及4级胆汁淤积,于治疗第40天死亡,死亡判定为疾病进展相关。
  • 未发生额外剂量限制性毒性,决定在1b期(n=81)维持雷莫芦单抗和帕博利珠单抗的全计划剂量。
  • 严重不良事件发生于92例中的53例(58%),其中22例(24%)判定为治疗相关。
  • 6例(7%)因治疗相关不良事件终止治疗,一例死亡(胃或胃食管交界腺癌患者的肺脓毒症)判定为治疗相关。

临床怎么用

  • 该联合方案在经治晚期胃食管癌、非小细胞肺癌和尿路上皮癌中安全性可控,可考虑进一步探索联合或不联合化疗。
  • 尤其对于单药检查点抑制剂相比化疗无额外获益的肿瘤患者,该联合方案值得进一步研究。

局限性

  • 非随机设计,样本量较小,各队列样本量有限。
  • 为1a/b期试验,主要终点为安全性,抗肿瘤活性为初步探索性结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pre-clinical and clinical evidence suggests that simultaneous blockade of VEGF receptor-2 (VEGFR-2) and PD-1 or PD-L1 enhances antigen-specific T-cell migration, antitumour activity, and has favourable toxicity. In this study, we aimed to assess the safety and preliminary antitumour activity of ramucirumab (an IgG1 VEGFR-2 antagonist) combined with pembrolizumab (an IgG4 PD-1 antagonist) in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma, non-small-cell lung cancer, or urothelial carcinoma. METHODS: We did a multicohort, non-randomised, open-label, phase 1a/b trial at 16 academic medical centres, hospitals, and clinics in the USA, France, Germany, Spain, and the UK. We enrolled adult patients aged 18 years or older with histologically confirmed gastric or gastro-oesophageal junction adenocarcinoma (cohorts A and B), non-small-cell lung cancer (cohort C), or urothelial carcinoma (cohort D), whose disease had progressed on one or two lines of previous therapy (for those with gastric or gastro-oesophageal junction adenocarcinoma) or one to three lines of previous therapy (for those with non-small-cell lung cancer and urothelial carcinoma) that included platinum (for all tumour types) or fluoropyrimidine or both (for gastric or gastro-oesophageal junction adenocarcinoma). Eligibility criteria included presence of measurable disease and an Eastern Cooperative Oncology Group performance status of 0-1. Patients with previously untreated gastric or gastro-oesophageal junction adenocarcinoma and non-small-cell lung cancer were also enrolled (in two additional separate cohorts); the results for these cohorts will be reported separately. The first 21-day treatment cycle was a dose-limiting toxicity observation period (phase 1a; safety run-in), followed by a phase 1b cohort expansion stage. Pembrolizumab 200 mg was administered intravenously on day 1, and intravenous ramucirumab was administered at 8 mg/kg on days 1 and 8 for cohort A or at 10 mg/kg on day 1 for cohorts B, C, and D, every 3 weeks, until disease progression or other discontinuation criteria were met. The primary endpoint was the safety and tolerability of ramucirumab in combination with pembrolizumab assessed by the incidence of adverse events in both phase 1a and 1b and as dose-limiting toxicities during phase 1a. The safety and activity analysis set included all patients who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov, number NCT02443324, and is no longer enrolling patients. FINDINGS: Between July 30, 2015 and June 24, 2016, we enrolled and treated 92 patients (41 with gastric or gastro-oesophageal junction adenocarcinoma, 27 with non-small-cell lung cancer, and 24 with urothelial carcinoma). Median follow-up was 32·8 months (IQR 28·1-33·6). During the first cycle of treatment (phase 1a safety run-in; n=11), one patient with gastro-oesophageal junction adenocarcinoma who received the 8 mg/kg dose of ramucirumab had grade 3 abdominal pain, colitis, hepatitis, interstitial lung disease, and jaundice, and grade 4 cholestasis, and died on treatment on day 40; the death was deemed related to progressive disease. No additional dose-limiting toxicities occurred and the decision was made to maintain the full planned doses of ramucirumab and pembrolizumab in phase 1b (n=81). Treatment-related adverse events occurred in 75 (82%) of 92 patients, the most common of which was fatigue (in 33 patients [36%]), predominantly of grade 1 or 2 severity. 22 patients (24%) had one or more treatment-related adverse events of grade 3 or worse, most commonly hypertension (six patients; 7%) and colitis (five patients; 5%). Serious adverse events occurred in 53 (58%) of 92 patients, and were deemed related to treatment in 22 (24%) patients. The most common treatment-related serious adverse events were abdominal pain in patients with gastric or gastro-oesophageal junction adenocarcinoma (in three [7%] of 41 patients); asthenia and myocardial infarction in patients with non-small-cell lung cancer (two [7%] of 27 patients), and colitis in patients with urothelial carcinoma (two [8%] of 24 patients). Six (7%) of 92 patients discontinued treatment because of treatment-related adverse events, and one death (from pulmonary sepsis in a patient with gastric or gastro-oesophageal junction adenocarcinoma) was deemed related to treatment. The number of patients achieving an objective response was three (7%; 95% CI 1·5-19·9) of 41 in the gastric or gastro-oesophageal junction adenocarcinoma cohort, eight (30%; 13·8-50·2) of 27 in the non-small-cell lung cancer cohort, and three (13%, 2·7-32·4) in the urothelial carcinoma cohort. INTERPRETATION: Ramucirumab in combination with pembrolizumab showed a manageable safety profile with favourable antitumour activity in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma, non-small-cell lung cancer, and urothelial carcinoma. Our results contribute to the growing evidence that supports dual inhibition of the VEGF-VEGFR2 and PD-1-PD-L1 pathways. This combination could be further explored with or without chemotherapy, especially for patients with tumours for which single-agent checkpoint inhibitors have shown no additional benefit over chemotherapy. FUNDING: Eli Lilly and Company, and Merck and Co.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Herbst RS, Arkenau HT, Santana-Davila R, et al. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. Lancet Oncol. 2019. PMID: 31301962. doi:10.1016/S1470-2045(19)30458-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。